UltraRapid Communication |
Inhibits TGF-ßInduced ß5 Integrin Transcription in Vascular Smooth Muscle Cells by Interacting With Smad4
From the Department of Medicine (U.K., C.L., S.W., D.B., W.A.H., R.E.L.), Division of Endocrinology, Diabetes and Hypertension, University of California, Los Angeles, School of Medicine, Los Angeles, Calif; Institute of Pharmacology and Toxicology (U.K.), Charité Hospital, Humboldt-University Berlin, Berlin, Germany; the Department of Medicine/Cardiology (D.B., S.G., K.G., E.F.), German Heart Institute Berlin, Berlin, Germany; the Department of Pathology (X.F.), University of Alabama, Birmingham, Ala; Ludwig Institute for Cancer Research (A.M.), Uppsala, Sweden; the Department dAtherosclerose (B.S.), UR545 INSERM, Institut Pasteur de Lille and Faculté de Pharmacie, Universitè de Lille II, Lille, France.
Correspondence to Ronald E. Law, PhD, UCLA School of Medicine, Division of Endocrinology, Diabetes and Hypertension, Warren Hall, Second Floor, Suite 24-130, 900 Veteran Ave, Box 957073, Los Angeles, CA 90095. E-mail rlaw{at}mednet.ucla.edu
Integrins play an important role in vascular smooth muscle cell (VSMC) migration, a crucial event in the development of restenosis and atherosclerosis. Transforming growth factor-ß (TGF-ß) is highly expressed in restenotic and atherosclerotic lesions, and known to induce integrin expression. Peroxisome proliferator-activated receptor
(PPAR
), a member of the nuclear receptor superfamily, regulates gene expression in a variety of vascular cells. We investigated the effects of PPAR
ligands on TGF-ßinduced ß3 and ß5 integrin expression and potential interaction between PPAR
and TGF-ß signaling. PPAR
ligands WY-14643 (100 µmol/L) and 5,8,11,14-eicosatetranoic acid (ETYA, 50 µmol/L) inhibited TGF-ßinduced ß5 integrin protein expression by 72±6.8% and 73±7.1%, respectively (both P<0.05). TGF-ßstimulated ß3 integrin expression was not affected by PPAR
ligands. Both PPAR
ligands also suppressed TGF-ßinduced ß5 integrin mRNA levels. PPAR
ligands inhibited TGF-ßinducible transcription of ß5 integrin by an interaction with a TGF-ß response element between nucleotides -63 and -44, which contains a Sp1/Sp3 transcription factor binding site. Nuclear complexes binding to the TGF-ß response region contained Sp1/Sp3 and TGF-ßregulated Smad 2, 3, and 4 transcription factors. TGF-ßstimulated Sp1/Smad4 nuclear complex formation was inhibited by WY-14643 and ETYA with a parallel induction of PPAR
/Smad4 interactions. However, in vitro pull-down experiments failed to demonstrate direct binding between PPAR
/Smad4. Both PPAR
ligands blocked PDGF-directed migration of TGF-ßpretreated VSMCs, a process mediated, in part, by ß5 integrins. The present study demonstrates that PPAR
activators inhibit TGF-ßinduced ß5 integrin transcription in VSMCs through a novel indirect interaction between ligand-activated PPAR
and the TGF-ßregulated Smad4 transcription factors. The full text of this article is available at http://www.circresaha.org.
Key Words: peroxisome proliferator-activated receptor
integrin transforming growth factor-ß vascular smooth muscle cell
This article has been cited by other articles:
![]() |
X. Ruan, F. Zheng, and Y. Guan PPARs and the kidney in metabolic syndrome Am J Physiol Renal Physiol, May 1, 2008; 294(5): F1032 - F1047. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. Sekiguchi, Q. Tian, M. Ishiyama, J. Burchfield, F. Gao, D. L. Mann, and P. M. Barger Inhibition of PPAR-{alpha} activity in mice with cardiac-restricted expression of tumor necrosis factor: potential role of TGF-beta/Smad3 Am J Physiol Heart Circ Physiol, March 1, 2007; 292(3): H1443 - H1451. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. Ichijo, A. Voutetakis, A. P. Cotrim, N. Bhattachryya, M. Fujii, G. P. Chrousos, and T. Kino The Smad6-Histone Deacetylase 3 Complex Silences the Transcriptional Activity of the Glucocorticoid Receptor: POTENTIAL CLINICAL IMPLICATIONS J. Biol. Chem., December 23, 2005; 280(51): 42067 - 42077. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Schupp, M. Clemenz, R. Gineste, H. Witt, J. Janke, S. Helleboid, N. Hennuyer, P. Ruiz, T. Unger, B. Staels, et al. Molecular Characterization of New Selective Peroxisome Proliferator-Activated Receptor {gamma} Modulators With Angiotensin Receptor Blocking Activity Diabetes, December 1, 2005; 54(12): 3442 - 3452. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. Guan Peroxisome Proliferator-Activated Receptor Family and Its Relationship to Renal Complications of the Metabolic Syndrome J. Am. Soc. Nephrol., November 1, 2004; 15(11): 2801 - 2815. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Schupp, J. Janke, R. Clasen, T. Unger, and U. Kintscher Angiotensin Type 1 Receptor Blockers Induce Peroxisome Proliferator-Activated Receptor-{gamma} Activity Circulation, May 4, 2004; 109(17): 2054 - 2057. [Abstract] [Full Text] [PDF] |
||||
|
Circulation Research Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search Copyright © 2002 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. |